CTXR · Insider Trading
Citius Pharmaceuticals Inc. Common
Every open-market purchase and sale reported by CTXR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-23 | Leonard L Mazur | Chief Executive Officer | MIXED | — | — |
| 2025-08-12 | Myron Z Holubiak | Vice Chairman | MIXED | — | — |
| 2024-11-12 | Robert Joseph Smith | Director | A | +125,000 deriv. | — |
| 2024-11-12 | Carol Webb | Director | A | — | — |
| 2024-11-12 | Eugene Myron Holuka | Director | A | — | — |
| 2024-11-12 | Dennis M McGrath | Director | A | +125,000 deriv. | — |
| 2024-11-12 | Myron Czuczman | Chief Medical Officer | A | +300,000 deriv. | — |
| 2024-11-12 | Myron Z Holubiak | Vice Chairman | A | — | — |
| 2024-11-12 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2024-11-12 | Suren G Dutia | Director | A | +125,000 deriv. | — |
| 2024-11-12 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2024-09-27 | Leonard L Mazur | Chief Executive Officer | MIXED | — | — |
| 2024-09-27 | Myron Z Holubiak | Vice Chairman | MIXED | — | — |
| 2024-08-30 | Eugene Myron Holuka | Director | MIXED | +2,367 | +$0 |
| 2024-08-30 | Carol Webb | Director | MIXED | +11,835 | +$0 |
| 2024-04-05 | Myron Z Holubiak | Vice Chairman | MIXED | — | — |
| 2024-04-05 | Leonard L Mazur | Chief Executive Officer | MIXED | — | — |
| 2024-03-18 | Robert Joseph Smith | Director | A | +75,000 deriv. | — |
| 2023-10-12 | Dennis M McGrath | Director | A | +75,000 deriv. | — |
| 2023-10-12 | Eugene Myron Holuka | Director | A | +75,000 deriv. | — |
| 2023-10-12 | Myron Czuczman | Chief Medical Officer | A | +300,000 deriv. | — |
| 2023-10-12 | Myron Z Holubiak | Vice Chairman | A | — | — |
| 2023-10-12 | Carol Webb | Director | A | +75,000 deriv. | — |
| 2023-10-12 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2023-10-12 | Suren G Dutia | Director | A | +75,000 deriv. | — |
| 2023-10-12 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2023-02-09 | Dennis M McGrath | Director | A | +75,000 deriv. | — |
| 2022-11-15 | Leonard L Mazur | Executive Chairman | — | — | — |
| 2022-10-06 | Myron Czuczman | Chief Medical Officer | A | +300,000 deriv. | — |
| 2022-10-06 | William Kane | Director | A | +75,000 deriv. | — |
| 2022-10-06 | Suren G Dutia | Director | A | +75,000 deriv. | — |
| 2022-10-06 | Carol Webb | Director | A | +75,000 deriv. | — |
| 2022-10-06 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2022-10-06 | Leonard L Mazur | Executive Chairman | A | — | — |
| 2022-10-06 | Eugene Myron Holuka | Director | A | +75,000 deriv. | — |
| 2022-10-06 | Howard Safir | Director | A | +75,000 deriv. | — |
| 2022-10-06 | Myron Z Holubiak | Vice Chairman | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Leonard L Mazur | Chief Executive Officer | 410,214 | $184.31K |
| Myron Z Holubiak | Vice Chairman | 79,690 | $35.80K |
| Jaime Bartushak | Chief Financial Officer | 2,414 | $1.08K |
| Carol Webb | Director | 473 | $213 |
| Eugene Myron Holuka | Director | 95 | $43 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTXR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.